* Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine candidate BNT113 based on BioNTech's FixVac platform * Initiated two Phase 2 dose optimization trials with BNT327/PM8002 in small- cell lung cancer and in triple-negative breast cancer to inform planned pivotal Phase 3 trials * Phase 2 clinical trial on track to evaluate mRNA-based individualized cancer vaccine candidate autogene cevumeran...